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PREFACE 
 There are a lot of issues in the United States but the stigmatization of the mentally ill is 
one often overseen. In writing this review, I hope to shine a spotlight on the current situation of 
mental illness research and treatment, and how it is in desperate need of reform and funding. 
Research has progressed to a point where biological etiology and pathophysiological explanation 
can be made for many disorders.  
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ABSTRACT 
Christopher Angerhofer: A Biological Review of Mental Illness: An Overview of Genetics and 
Pathophysiology of Addiction, Major Depression, and Schizophrenia 
(Under the direction of Greg Heiberger) 
 
 Novel approaches in understanding mental illness present solutions to current issues in 
treatment and diagnosis. With advancements in genetics and neurology, the etiology and 
pathophysiology of mental illness is slowly unwrapping. In discovering biomarkers for 
depression, addiction, and schizophrenia, the precision for preventing, diagnosing, and treating 
these disorders increases. The aim of this paper is to review current research for addiction, major 
depression, and schizophrenia in genetics and physiology, while also clarifying the need for 
reclassifying mental illness as diseases with a pathophysiological basis, not syndromal, 
idiopathic disorders. Mental illness is dynamic in that it encompasses both environmental and 
biological factors, but research emphasis on the latter has potential to improve the treatment of 
disorders, and possibly prevent them.  
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INTRODUCTION 
 
MENTAL ILLNESSS & SOCIETY 
Despite the advances in modern 
medicine over the last century, 
understanding and treatment for mental 
illness has remained rather stagnant[5]. 
Other areas of medicine have adopted a 
proactive approach to deter the onset of 
serious illnesses and disorders, while 
developments in psychiatry have remained 
primarily therapeutic. With recent advances 
in genetics and neurology, research in 
mental illness has progressed faster than 
ever although, the dynamic nature of mental 
illness has made this progress difficult. 
Mental illness is not characterized by 
biology alone and the influence of 
environmental variables can make them 
unpredictable[6]. 
Although research in this field has 
progressed significantly, the burden of 
mental illness is still present. Psychiatric 
disorders require extensive care due to their 
severity and frequency. Mental illness is 
socially, economically, cognitively and 
behaviorally detrimental. These illnesses 
don’t affect just the individual, but also their 
families and communities. In the United 
States alone, nearly fifty percent of people 
will be diagnosed with a mental illness in 
their lifetime[7]. Without significant 
changes in how mental illness is viewed and 
treated, this is unlikely to change anytime 
soon[8]. 
Mental illness is expensive to both 
the individual and the community. In the 
United States alone, the combined annual 
costs of substance abuse and anxiety 
disorders is estimated to be around $542 
billion. This accounts for the cost of 
criminal justice, medical, accidents, and loss 
of earnings. In total, psychiatric illness 
accounts for approximately 6.2% of the 
nation’s health care expenditure. The 
economic impact in the individual has been 
difficult to determine, but in a door to door 
survey conducted by the National 
Comorbidity Survey Replication (NCS-R), 
there is an estimated earning loss of $16,306 
per individual with a serious mental illness 
that accumulates to approximately $193.2 
billion annually. This estimate is very 
conservative in that it does not account for a 
multitude of other factors. When including 
factors such as disability benefits, public 
housing, food stamps, etc. the actual 
estimate is closer to $317 billion annually, 
and this still doesn’t account for incarcerated 
persons, comorbid conditions, or early 
mortality related costs[8, 9]. 
Stigmatization plays a significant 
role in the issues plaguing mental illness in 
healthcare. The diagnosed contend with both 
the disorder itself and the negative 
connotation society has place on it[10]. 
There are two separate parameters to this 
prejudice wherein stigmatization is self-
inflicted as much as it is socially imposed. 
Western and European cultures are infamous 
for their stigmatization of mental illness 
which often extends to even medical 
professionals. Benevolence, fear and 
exclusion, and authoritarianism are three 
distinct traits that individuals diagnosed with 
a mental illness often express due to this 
stigmatization[6]. Insofar, the most effective 
method in combatting this issue has been, 
and will continue to be, education and 
awareness[10].  
While stigmatization poses a 
significant social issue, cognition deficits are 
typically more of an issue with severe 
A BIOLOGICAL REVIEW OF MENTAL ILLNESS  
2 | P a g e  
 
disorders like schizophrenia, though 
problems are noted in more common 
disorders as well[11]. These affects are 
noted by a decline in working memory, 
executive function, and attention and 
information processing. Initial illness 
coupled with lethargic medication 
compound this issue. Thus, a major obstacle 
for those with disorders is job retention and 
the need for cognitive treatment and 
rehabilitation to live normal lives[12].  
Unfortunately, mental illnesses are 
rising in adults, young adults and 
adolescents, with significant increases in the 
latter two[13] . The increasing incidence and 
prevalence of mental illness will amplify the 
issues discussed above. This is further 
justified by figure one that shows emergency 
department visits due to mental health have 
increased as well[14]. Another ongoing 
issue promising to heighten the severity of 
this situation is the opioid epidemic that 
plagues the United States. Comorbid 
addiction is fairly common in serious mental 
illnesses, with studies showing nearly 50-
60% of individuals with schizophrenia also 
having a substance abuse issue[15]. Each 
year, opioid related deaths increase in both 
accidental overdosing and suicide related 
deaths[16]. This trend shows a need to 
increase research and funding in addiction 
and depression to directly combat this 
national epidemic. Though the main culprit 
in this situation is the painkiller 
hydrocodone, other psychoactive drugs have 
been implicated as well. A new method of 
treating addiction, depression and 
schizophrenia is desperately needed. 
Traditional pharmaceutical therapeutic 
approaches work to some extent, but 
antipsychotics can have severe side effects 
with some long term use leading to 
neurological issues like tardive 
dyskinesia[17]. Through novel genotyping 
and neuroimaging practices, precision 
medicine can be practiced with psychiatric 
diagnosis and care [5]. 
 
 
Figure 1. National trends in mental health-
related emergency department visits per 1,000 U.S 
population, by disorder category, 1992 to 2001[14]. 
 
DIAGNOSTIC ISSUES 
 Diagnosing mental disorders has 
traditionally been done using the Diagnostic 
and Statistical Manual of Mental Disorders 
(DSM), which originated as a variant of the 
International Classification of Diseases 
(ICD),  of which diagnose using a primarily 
symptom-based approach. As of this review, 
the manual stands on its fifth edition (DSM-
V) which was recently constructed in 2000 
and published in 2013, has improved 
immensely since its fruition in 1952[18]. 
Developed by the American Psychological 
Association (APA), it is a classification 
system that currently holds diagnostic for 
297 conditions[18]. Significant changes 
from the DSM-IV to the DSM-V include 
nomenclature, a reworking of the multiaxial 
system and the introduction of dimensional 
assessments which is aimed at diagnosing 
subtypes of disorders[19]. 
 As science and research have 
advanced, the DSM has been highlighted 
with major criticisms with its nosology. 
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Until the most recent edition, diagnostic 
criteria had been primarily description 
based, almost entirely ignoring an etiology-
based approach to mental illness. A major 
criticism in development of the current DSM 
structure is that the disorders it defines were 
developed with little validity[20, 21]. 
Though the defining characteristics of 
illness and disorders were developed with an 
objective, empirical method of observation, 
they stem from an almost entirely 
psychoanalytic perspective and many fail to 
account for the biological nature of mental 
illness[22]. 
 This leads into the issue of a lack of 
a disease progression system in psychiatric 
healthcare. Most clinical pathologies are 
defined and treated according to their 
clinical stage of development. This works to 
judge the severity of disease and provides a 
better baseline in developing an effective 
treatment strategy. This method of 
evaluation has remained mostly absent in 
psychiatric medicine to this day[23]. The 
importance of such a structure comes into 
play when attempting to prevent either 
disease progression or regression. By 
denoting a stage of severity in mental 
illnesses, treatment strategies can be 
developed that deter disease progression 
through both biological and environmental 
means. The prevention of regression in more 
severe stages is another issue the current 
diagnostic model fails to account for. In the 
process of effective psychiatric treatment, 
theses constructs are just as important as 
they would be in other medical 
pathologies[23]. 
 Another significant issue with the 
DSM is the “box canyon problem”[24]. This 
problem analogizes that psychiatric 
diagnosis has dug itself into an inescapable 
hole, the box canyon, and criticizes that the 
criteria for diagnosis has been systematically 
built upon instead of developing a new, 
independent diagnostic tool. This method of 
revision is in and of itself unscientific in that 
it assumes the previous model of diagnosis 
was correct. This evolutionary method of 
nosology has constricted the understanding 
of mental illness. The development of the 
DSM-III in the 1980’s marked a noted 
significant increase in the reliability of 
diagnosis from both the DSM-I and DSM-II, 
but it’s reliability has remained mostly 
unchecked since[25]. 
 This is all not to say the DSM should 
be completely discarded, but that a new 
approach should be researched that can 
improve the efficacy of diagnosis and 
treatment. A more pragmatic approach that 
utilizes current scientific and clinical 
technology to define mental illness should 
be integrated into the current model. To fix 
the box canyon problem, a new framework 
must be built. The DSM is a starting point 
and with the addition of genetics and 
pathophysiology, treating mental illness can 
be more effective[1].  
MATERIAL AND METHODS 
 In writing this review, Web of 
Science - All Databases and Google Scholar 
were used for searching relevant research 
articles. Wikipedia pages were used to gain 
a basic understanding of some subject 
material and to acquire additional references 
and primary literature articles. To ensure 
that the information this review provides is 
accurate and relevant to the scientific 
community, the vast majority of sources are 
no older than the year 2000. 
 Keywords used in finding research 
articles were; biomarkers, genetics, and 
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pathophysiology. Each of these was 
searched in conjunction with the respective 
disorders evaluated in this review. 
Schizophrenia, depression, and addiction 
were chosen as the three disorders in this 
review due to promising research and shared 
pathophysiological traits[26]. 
 
GENETICS 
 
IDENTIFICATION METHODS 
 With the significant progression in 
genotyping technology in the twenty-first 
century and the completion of the Human 
Genome Project in 2003, a new era of 
medicine was born[27]. This new 
technology has the potential to correlate 
genetic variants with various psychiatric 
disorders. Not only does this show promise 
in a diagnostic capacity, but in therapeutic 
one as well. Identification of common 
markers for specific disorders can denote 
which forms of treatment may be most 
effective in a particular case. Medications 
for treatment can then also be personalized 
based on the individual’s genetic 
architecture[27].  
Psychiatric disorders presented many 
issues in the first attempts to correlate genes 
with illness. One of the first genotyping 
methods using high-throughput sequencing 
studied single nucleotide polymorphisms 
(SNPs). Researchers quickly realized that 
there could be a multitude of SNPs in one 
gene and this method was abandoned as 
technology wasn’t advanced enough to 
provide timely results. Fortunately, the 
concept of linkage disequilibrium (LD) 
solved this issue in that only a portion of 
SNPs need be mapped to determine common 
structural variants (SV). This led to linkage 
analyses that could test for rare mutations 
with high penetrance and heritability in a 
small population of alleles. Most linkage 
analyses results reveal Mendelian 
inheritance patterns[28]. 
As genotyping methods improved, 
Genome-Wide Association Studies (GWAS) 
became an invaluable tool that made 
possible the mapping of millions of SNPs in 
a genome of large populations of 
individuals. Microarrays, and other 
genotyping arrays, have allowed the 
identification of common SV in association 
with many mental disorders today. The main 
drawback of GWAS is the phenomenon that 
it is unable to prove strong heritability of 
gene[29, 30]. 
 Beyond the specific types of 
genomic sequencing, a vital aspect to this 
research is the methods by with the 
information is obtained and interpreted. 
Genetic research designs fall under two 
categories; case-control or pedigree studies. 
The first, which is most often utilized in 
GWAS, looks for how many genetic 
variations are present in a specific 
population and then compares that number 
to an appropriate control. This type of 
design is simple and is efficient at 
eradicating possible bias. The primary 
limitation of case-control studies is the lack 
of Mendelian genetics, and thus no ability to 
discern de novo mutations[29]. 
 Pedigree studies, following a specific 
phenotype through family ancestry,  can 
achieve what case-control cannot and are 
divided into the subcategories of simplex 
and multiplex[31]. Simplex pedigree studies 
compare an affected individual with 
unaffected relatives. This case design has 
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been typically associated as the best method 
of studying de novo mutations that correlate 
with mental illness. Multiplex pedigree 
studies are the most common form of 
pedigree study and consist of phylogenic 
study with multiple affected individuals of 
relation. The primary reason for widespread 
use is that high-penetrance mutations within 
a family are can be linked for causation[29].  
GENE ASSOCIATIONS 
 To date, there have been many 
genetic associations made with various 
mental illness. An important concept in this 
research is that in identifying candidate 
genes with mental illness associations, the 
results are not going to lead to single variant 
on one gene[29]. The interplay between 
phenotype and genotype denotes that a 
multitude of genes contribute to phenotype, 
and this is especially true in the case of 
mental illness. Therefore, early research that 
yielded results in gene associations, 
especially with schizophrenia, was met with 
significant criticism because of the 
complexity of genetics[2].  
In the search for a genetic 
association to mental disorders, 
Schizophrenia has essentially stood as the 
poster child for promising research. With a 
heritability of approximately 80%, a genetic 
component of schizophrenia was almost 
certain[32]. Early results in this research 
were met with criticism as duplication 
efforts were seemingly unsuccessful due to 
the presence of multiple alleles and 
Table 1. Schizophrenia susceptibility genes and the strength of evidence in four domains. Most of the 
identified loci are a result of linkage analyses[2]. 
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haplotypes[2]. As research and technology 
progressed though, table one shows that 
over a dozen genes have been implicated in 
increased susceptibility for schizophrenia[2]. 
Fortunately, linkage analysis studies have 
revealed that schizophrenia has a strong 
genetic component. This has mostly been 
attributed to the fact that multiple 
susceptibility genes are found in linked 
regions[2]. The high genetic heritability of 
schizophrenia has made link analyses 
particularly successful.  
In studies attempting to discern gene 
associations for major depression, results 
have been slow and inconsistent. Very few 
studies have actually been conducted, and 
where they have, the sample sizes have not 
been large enough to hold external 
validity[33]. Despite these setbacks, recent 
research has yielded promising results. In a 
2010 study conducted in a Swedish 
population-based cohort, four candidate 
genes have been identified that show a 
suggestive association with depression[34]. 
Use of the terminology “suggestive 
association” is used by the authors to imply 
that further research of these four candidate 
genes is necessary to confirm their genetic 
associations with major depression. 
The epidemiology of depression has 
always suggested that a strong genetic 
component is involved[35]. As more 
research is conducted on the genetics of 
depression, results are indicating a high 
percentage of heritability in nearly every 
study[36]. Many recent studies have begun 
to report a heritability of just under 80%, 
which is similar to schizophrenia’s 
heritability, while others have reported 
lower stating that major depression involves 
a genetic component of ~ 40%[36]. The 
discrepancy in this research is most likely 
attributed to the associated genes being 
undetectable in linkage studies due to their 
Table 2. Alcohol and nicotine addiction susceptibly genes, and their functions, identified in a Genome 
Wide Association Study(GWAS)[3]. 
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low effect size[33]. These results have 
strengthened the assertion that major 
depression is not solely based on one gene, 
but interplay of several different loci.  
Another obstacle in the quest to 
delineate genes associated with major 
depression is the heterogeneity of the 
disorder. The polygenic nature of major 
depression has commonly led to an overlap 
in findings associated with the identification 
of genetic determinants for other disorders. 
These results indicate that formulating 
specific subtypes of depression may yield 
more accurate results when attempting to 
search for associated genes[37]. 
 Addiction encompasses a broad 
category of mal-adaptive behaviors signified 
by compulsive and uncontrollable substance 
abuse or activity[3, 38, 39]. As one of the 
most significant mental illness in society, 
identifying associated genes is of utmost 
importance in combating it. Addiction can 
be further subdivided into the two categories 
of behavioral addictions (e.g. gambling, sex, 
shopping, etc.) and substance abuse 
addictions. Both are relevant in this context 
as genetic associations have been made in 
each category[3]. 
 Numerous candidate genes have 
been identified for the various forms of 
addiction. Table two outlines candidate 
genes that have been identified in alcohol 
and nicotine dependence[3]. The genes 
listed above have shown the highest 
association with these two types of 
substance abuse, as confident replication in 
identifying associated genes in other forms 
of addiction has been notably lacking. 
Currently, identified genes can also be 
divided into two separate categories as well. 
The first consists of substance specific 
genes, and the second category consists of 
genes identified with high risk behaviors, 
such as impulsivity[3].  
 The heritability of addiction has been 
extensively studied and results have 
provided interesting insight into this 
disorder. Rates of heritability differ from 
substance to substance, but each hover 
around 50%[40]. In further assessing the 
genetic influence of addiction, stages of this 
disorder show differing heritability. When 
addiction is broken down into three stages of 
initiation, chronic use, and addiction, the 
effects of heritably are dependent on the 
stage of the disorder. It is found to be 
weakest during initiation and strongest in 
last two stages[3]. 
 A significant issue in researching 
genetic associations of addiction is the high 
amount of comorbidity present in this 
disorder. Addiction is commonly comorbid 
with other forms of addiction, as well as, 
other mental illnesses[39]. An explanation 
for high comorbidity is derived the from the 
second category of associated genes, 
discussed above, in that high-risk behavior 
genes correlate with further maladaptive 
behavior. As a result of this issue, research 
into specific genetic associations in relation 
to individual substances has been limited[3]. 
 
PATHOPHYSIOLOGY 
 
ALTERED GENE EXPRESSION 
 Discovering genes associated with 
psychiatric illness is important research but 
knowing what those genes transcribe for is 
the next step in making this research 
clinically relevant. Genome wide gene 
expression (GWGE) studies are a research 
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method similar to GWAS. Instead of 
focusing on solely genetic architecture, and 
the SVs therein, GWGE studies offer a 
method of observing both DNA and RNA in 
a hybrid model[28]. This method of research 
is important in discerning the etiology of 
diseases by comparing the expression of 
mRNA between a control and experimental 
group[28]. 
BIOMARKERS 
Current research has been focused on 
developing various novel methods to 
diagnose psychiatric disorders[41-44]. 
While currently there is no certainty in 
biological markers for diagnosis, progress is 
being made and shows promise. Research is 
taking multiple approaches in identifying 
psychiatric disorders utilizing proteins 
markers in easily accessible fluids, genetic 
markers, and inflammatory markers such as 
cytokines or hormones[41]. This type of 
diagnosis allows for specific and 
individualized care and has started to 
redefine what is known about current 
disorders. A prime example of this is the use 
of motion-related Blood-oxygen-level 
dependent (BOLD) signal effects in defining 
subtypes of depression[45]. The 
symptomatic diagnostic approach currently 
in practice has led to a generalization of 
symptoms that can defined by one or more 
disorders, while research is showing that 
mental illness can be more precisely defined 
by pathophysiological abnormalities[46].  
Due to the debilitating nature of 
schizophrenia, there has been a significant 
amount of research done in diagnosing this 
disorder. The field of transcriptomics, 
identifying genetic variations associated 
Figure 2. Microglial activation hypothesis in the pathophysiology of schizophrenia. The left most column, 
iNOS, DAMPS, Iba-1, and HSP70s, are examples of increased pro- inflammatory cytokines commonly seen in 
schizophrenia. They activate M1 and M2 microglial cells, which in turn upregulate immune system effectors, IL-1β, 
IL-6, TNF-α, and ROS, responsible for symptoms and pathophysiology associated with schizophrenia.  
DAMPS=damage-associated molecular patterns; Iba-1=ionized calcium binding adaptor molecule 1; iNOS=nitric 
oxide synthase; HSP70s=shock 70-kDa proteins; RAGE=glycation end-products receptor; ROS=reactive oxygen 
species; TNF-a=tumor necrosis factor-a[4]. 
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with pathological illness, has shown 
immense success in cancer research and 
therefore, has taken the lead role in 
identifying biomarkers associated with 
schizophrenia[47].  Using gene ontology 
enrichment studies, gene association to 
function can be derived. Consistent with 
other research, these studies have revealed a 
relationship between altered metabolism, 
neural development/function, and immune 
response with schizophrenia pathology. 
Figure two reveals a pathway in which the 
immune system may play in the 
pathogenesis of schizophrenia[4]. 
Like schizophrenia, inflammation 
has also been indicated in major 
depression[43]. When compared to 
individuals without depression, both healthy 
and unhealthy depressed individuals show 
signs of inflammation. Symptoms of 
depression appear to be side effects of the 
upregulation of pro inflammatory which 
have various effects on neurotransmitter 
metabolism, neuroendocrine function, and 
neural plasticity[43]. Notably, dopamine 
synthesis and serotonin availability are 
compromised in depressed individuals[43]. 
Another approach in identifying depression 
has been using resting state fMRI (rsfMRI) 
to recognize abnormalities in frontostriatal 
and limbic brain networking[45]. Using this 
method, researchers have been able to define 
four subtypes of depression based on 
abnormal connectivity[45]. This type of 
research provides an additional avenue to 
diagnosing and treating depression beside 
the symptomatic descriptive method 
currently used.  
Research in identifying biomarkers 
in addiction has been mostly concerned with 
Table 3. Example of RDoC organization[1]. 
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the dopamine pathway[48, 49]. The most 
consistent finding in addiction imaging is 
the reduction of striatal D2 receptor binding 
in individuals with addiction problems, 
though reductions in D1 receptors have been 
indicated also[48, 49]. The decreased 
binding of dopamine in the striatal region 
effects the circuitry of the prefrontal cortex 
and therefore dysregulating impulsivity 
control[49]. Therefore, mutations or 
modifications to D2 receptors can actually 
be predictive of addictive behavior[48]. 
 
PROSPECTIVE RESEARCH 
 
NOVEL DIAGNOSTIC METHODS 
A recent initiative to modify current 
mental illness diagnosis has been dubbed the 
Research Domain Criteria (RDoC), which 
aims to take a more dynamic approach in 
identifying mental illness by focusing on 
biology-based criteria[1, 6]. The two current 
diagnostic methods for identifying mental 
illness are the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) and the 
International Classification of Diseases 
(ICD), both of which were developed before 
modern neuroscience and thus do not 
coincide nicely with some new findings in 
this field[6]. Therefore, the National 
Institute of Mental Health (NIMH) initiated 
the RDoC to design a more comprehensive 
diagnostic system that include genetics, 
physiology, and neuroscience alongside 
behavioral dimensions[1].  
The RDoC, in its current state, is 
more of a research database rather than a 
diagnostic tool to be used in a clinical 
setting[6, 50]. It is different from the 
currently used diagnostic manuals in that it 
is a matrix of information that can 
continuously be modified as research 
advances, similar to how the National 
Database for Autism Research (NDAR) is 
currently being used[6]. Table three shows 
how the RDoC relates Domains/Constructs 
to different measurable units where the 
intersecting points will be filled with 
research in that particular area[1]. The goal 
of this research is to enter a new stage of 
precision medicine for psychiatric 
illnesses[50].  
Clinical staging of mental illness 
aims to adapt the same model of disease 
progression associated with other clinical 
pathologies to develop more specific 
treatment regimens[23]. Using tools such as 
the RDoC, psychiatric medicine can engage 
in precision medicine that can specifically 
target various stages of mental illness 
progression. Staging is quite common in 
other areas of medicine such as in cancer 
and heart disease, yet this same ideology is 
rarely applied to psychiatric illness[23, 51]. 
Disease staging has immense therapeutic 
and preventative potential. By identifying 
and utilizing biomarkers, mental illness can 
be mapped into different stages of disease 
progression based off of brain structure, 
inflammation levels, and neuroendocrine 
markers[52].  
GENE & STEM CELL THERAPY 
 Discovering genetic and 
physiological biomarkers for mental illness 
opens the door for new treatment methods. 
Moving beyond conventional 
pharmacological remedies for mental 
illnesses, both gene therapy and stem cell 
therapy have had success in mouse models 
treating different forms of mental illness. In 
one study, researchers were able to reduce 
depression-like behavior in mice with the 
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administration of an adeno-associated virus 
(AAV) into the nucleus accumbens to 
restore p11 protein expression[53]. Humans 
diagnosed with depression show low rates of 
p11 expression and mice with a p11 
knockout mutation show depressed 
behavior, making this biomarker a good 
candidate for gene therapy in treating 
depression.  
 Researchers may have also 
discovered a treatment for alcohol addiction. 
Neuroinflammation, caused by chronic 
ethanol intake and indicted as the cause for 
perpetual alcohol use, was abolished in mice 
with the administration of human 
mesenchymal stem cells (hMSCs) into a 
brain lateral ventricle[54]. The result of this 
stem cell therapy is that within a 24hr 
period, chronic alcohol consumption was 
reduced by 70% and relapse-like alcohol use 
was reduced by 80%. This study is another 
example showing the potential effectiveness 
of novel mental illness treatment strategies.  
 
CONCLUSIONS 
 
IMPLICATIONS 
 As research in psychiatry advances, 
the etiology and pathophysiology of mental 
illness clarifies. With this comes the ability 
to develop prevention strategies based on 
genetic heritability or provide specific 
therapy to stop disorders from worsening. 
Personalized medicine can be developed 
based on the genotype of an individual and 
this medicine can be used in a stage specific 
manner depending of the severity of the 
disorder. The biological component of 
psychiatric medicine will benefit immensely 
from this research, and combined with 
proper psychotherapy, the goal lifelong 
remission is one step closer for many.  
While these medical advances in 
psychiatry show promise, they may not be 
welcome in some respects. The ethical 
implications of a biological-based approach 
to mental illness has many pros and cons to 
take into consideration. Unexpected issues 
that may arise are testing costs, reliability, 
and discrimination[41]. As research in 
genetics advances, the idea of genetic 
existentialism often accompanies it, which is 
the idea that we are simply nothing more 
than what are genes code for[5]. This 
ideology has both positive and negative 
consequences. Genetic existentialism beliefs 
can take responsibility off the patient for 
having a mental illness, but at the same time, 
studies have shown that it can lead to public 
discrimination and self-stigmatizing  [5].  
LIMITATIONS 
 Small sample size is a consistent 
issue in most genetic studies on mental 
health. Finding a sample size that holds 
external validity is difficult when 
researching disorders that have low 
incidence and prevalence, such as 
schizophrenia.  
 When considering the etiology of 
mental illness, environment plays much too 
large of a role to be ignored. The complexity 
of translation and transcription is further 
multiplied due to the influence that 
environmental stressors can have on gene 
expression. Concentrating solely on one or 
the other is not what this review endorses, 
but to instead understand the various 
influences that cause the manifestation of 
mental illness. 
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APPENDICIES 
 
APPENDIX A 
 References are in APA format with 
numbered citations. The majority of this 
review’s style is based off UNC’s Graduate 
Thesis/ Dissertation Guide, that can be 
found at; 
https://gradschool.unc.edu/academics/thesis-
diss/guide/. A two-column format was 
selected for consistency to coincide with the 
other dissertations from the Human Biology 
M.S. cohort of 2018.  
 
APPENDIX B 
 Reviewer Feedback; 
Like you, my prayer is that one day we will 
understand the biological underpinnings of 
schizophrenia, which has like 17 different 
subtypes and proposed etiologies, 
depression, my own personal demon, and 
addictions...C.S. Lewis described alcohol or 
gambling manias as problematic by 
society, but we turn a blind eye to golfing or 
shopping manias...yet the neurobiological 
circuitry is the same...only societies 
condemnation of one and blessing of other 
determines need for research dollars.  
DSM is not perfect, and we need biological 
understanding of mental illnesses...but...until 
you new minds solve this for us, the DSM 
has improved our ability to talk, research, 
and accurately...mostly, analyze the myriad 
of symptoms afflicting our patients, and find 
the constellation of symptoms best matching 
a diagnosis...which accurately treats current 
symptoms. 
While I have whole heartedly embraced 
pharmacogenomic testing and use it 
regularly in my practice, it only provides 
presently liver metabolic level information 
and not molecule receptor specifics, still 
remains a game changer in my practice. I 
still hold out for germ line change of target 
SNP's through viral vectors in my life 
time...but one can only hope...and keep 
researching. 
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